Physician profile
Eric S Runyon
NPI 1225095268
$1,325.76
in general payments reported to CMS, 2019-2025
20 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.77 · 2020: $99.36 · 2021: $148 · 2022: $154 · 2023: $137 · 2024: $330 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $836.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $402.11 | 2019-2025 | Liletta, Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $202.61 | 2022-2025 | |
| Coopersurgical, INC. | $134.83 | 2021-2025 | Paragard T 380a |
| Evofem Biosciences, INC. | $134.09 | 2024-2025 | Phexxi, Solosec, Phexx |
| Biogen, INC. | $78.39 | 2025 | Zurzuvae |
| Biotissue Holdings INC. | $51.16 | 2024 | |
| Pfizer INC. | $47.74 | 2024-2025 | |
| Millicent US INC | $44.37 | 2020-2021 | |
| Astellas Pharma US INC | $43.59 | 2024-2025 | Veozah |
| Aroa Biosurgery Incorporated | $37.10 | 2024 | |
| Hologic Sales and Service, LLC | $25.57 | 2024 | Thinprep 2000 Processor, Aptima |
| Avanos Medical | $20.51 | 2019 | |
| Allergan, INC. | $19.38 | 2019 | |
| Exeltis, USA INC. | $18.20 | 2024 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $17.78 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mission Pharmacal Company | $15.60 | 2020 | |
| Guard Medical INC. | $13.49 | 2024 | Npseal Large |
| Duchesnay USA Incorporated | $12.18 | 2019 | |
| Organon LLC | $7.06 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Runyon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.